BRUKER CORP
Business
Bruker Corp is a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions for life and materials science research. The company offers magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, and molecular spectroscopy technologies across academic research, biopharmaceutical, applied markets, clinical diagnostics, and nanotechnology sectors. Bruker operates four reportable segments: BSI BioSpin (magnetic resonance and preclinical imaging), BSI CALID (mass spectrometry, microbiology diagnostics, and spectroscopy), BSI NANO (X-ray, microscopy, spatial biology, and metrology), and BEST (superconducting materials and accelerator components). The company maintains sales and service operations globally through direct sales forces and indirect distribution channels.
Summary from 10-K filed 2026-02-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 3,437 | 3,366 | 2,965 | 2,531 | 2,418 | |
| Total cost of revenue | 1,859 | 1,717 | 1,451 | 1,225 | 1,208 | |
| Gross profit | 1,578 | 1,650 | 1,513 | 1,306 | 1,210 | |
| Selling, general and administrative | 947 | 894 | 729 | 607 | 561 | |
| Research and development | 395 | 377 | 295 | 236 | 221 | |
| Goodwill impairment charge | 97 | 0 | 0 | — | — | |
| Other charges, net | 71 | 126 | 52 | — | — | |
| Total operating expenses | 1,510 | 1,396 | 1,076 | 873 | 796 | |
| Operating income | 68 | 253 | 437 | 433 | 413 | |
| Bargain purchase gain and associated measurement period adjustments | 0 | −8 | 144 | 0 | — | |
| Interest and other expense, net | −46 | −38 | −37 | −19 | −20 | |
| Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | 22 | 207 | 544 | 414 | 394 | |
| Income tax provision | 29 | 91 | 118 | 116 | 113 | |
| Equity in (losses) income of unconsolidated investees, net of tax | −1 | −2 | 2 | 1 | — | |
| Consolidated net (loss) income | −8 | 114 | 429 | 299 | 281 | |
| Net income attributable to noncontrolling interests in consolidated subsidiaries | 300,000 | 700,000 | 1 | 2 | 4 | |
| Net (loss) income attributable to Bruker Corporation | −9 | 113 | 427 | 297 | 277 | |
| Dividends on Series A Mandatory Convertible Preferred Stock | 14 | 0 | 0 | — | — | |
| Net (loss) income attributable to Bruker Corporation common shareholders | −23 | 113 | 427 | — | — | |
| Basic (per share) | −0.15 | 0.76 | 2.92 | 2 | 1.83 | |
| Diluted (per share) | −0.15 | 0.76 | 2.9 | 1.99 | 1.81 | |
| Basic (shares) | 152 | 149 | 146 | 148.6 | 151.4 | |
| Diluted (shares) | 152 | 150 | 147 | 149.4 | 152.9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 299 | 183 | 488 | 646 | 1,068 | |
| Accounts receivable, net | 545 | 566 | 492 | 473 | 417 | |
| Inventories | 1,095 | 1,068 | 968 | 800 | 710 | |
| Other current assets | 274 | 237 | 216 | 194 | 172 | |
| Total current assets | 2,213 | 2,053 | 2,164 | 2,113 | 2,472 | |
| Property, plant and equipment, net | 745 | 669 | 600 | 487 | 406 | |
| Goodwill | 1,548 | 1,507 | 583 | 458 | 340 | |
| Intangible assets, net | 900 | 913 | 331 | 271 | 212 | |
| Operating lease assets | 166 | 146 | 92 | 51 | 60 | |
| Deferred tax assets, net | 422 | 286 | 297 | 77 | 90 | |
| Other long-term assets | 249 | 233 | 184 | 155 | 71 | |
| Total assets | 6,241 | 5,807 | 4,250 | 3,612 | 3,650 | |
| Current portion of long-term debt and finance lease obligations | 17 | 33 | 121 | 19 | 112 | |
| Accounts payable | 216 | 234 | 203 | 178 | 147 | |
| Current portion of deferred revenue and customer advances | 441 | 438 | — | 218 | 198 | |
| Other current liabilities | 605 | 577 | 478 | 347 | 481 | |
| Total current liabilities | 1,279 | 1,281 | 1,202 | 914 | 939 | |
| Long-term debt | 1,853 | 2,062 | 1,160 | 1,201 | 1,222 | |
| Long-term deferred revenue and customer advances | 109 | 100 | 92 | 102 | 50 | |
| Deferred tax liabilities | 113 | 119 | 68 | 62 | 46 | |
| Operating lease liabilities | 139 | 119 | 75 | 35 | 42 | |
| Other long-term liabilities | 239 | 311 | 240 | 121 | 162 | |
| Total liabilities | 3,731 | 3,992 | 2,837 | 2,480 | — | |
| Commitments and contingencies (note 25) | — | — | — | — | — | |
| Redeemable noncontrolling interests | 37 | 18 | 19 | 6 | 200,000 | |
| Common stock, par value $0.01; Authorized - 260,000,000 shares Issued - 183,047,629 shares (2024: 182,456,831); Outstanding - 152,143,041 shares (2024: 151,677,952) | 2 | 2 | — | — | — | |
| Treasury stock, at cost Purchased - 30,904,588 shares (2024: 30,778,879) | −1,242 | −1,237 | −1,237 | −1,085 | −820 | |
| Additional paid-in capital | 1,415 | 713 | 283 | 256 | 238 | |
| Retained earnings | 2,362 | 2,407 | 2,324 | 1,926 | 1,660 | |
| Accumulated other comprehensive loss, net of tax | −80 | −104 | 6 | 15 | −8 | |
| Total shareholders' equity attributable to Bruker Corporation | 2,457 | 1,781 | 1,377 | 1,114 | 1,071 | |
| Noncontrolling interests in consolidated subsidiaries | 17 | 16 | 17 | 12 | 14 | |
| Total shareholders' equity | 2,474 | 1,797 | 1,395 | 1,126 | 1,085 | |
| Total liabilities, redeemable noncontrolling interests and shareholders' equity | 6,241 | 5,807 | 4,250 | 3,612 | 3,650 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 220 | 184 | 115 | 89 | 89 | |
| Stock-based compensation expense | 20 | 25 | 31 | 28 | 17 | |
| Deferred income taxes | −105 | −64 | −24 | −15 | −6 | |
| Impairment of goodwill, intangible assets, other long-lived assets, and certain minority investments | 152 | 29 | 22 | — | — | |
| Write down of inventories | 76 | 60 | 19 | — | — | |
| Acquisition-related hybrid liability adjustments | −49 | 20 | −7 | — | — | |
| Foreign currency transaction (gain) loss, net | −56 | −28 | 19 | — | — | |
| Other non-cash expenses, net | 28 | 22 | −21 | 27 | 28 | |
| Accounts receivable | 54 | −41 | −900,000 | −68 | −95 | |
| Inventories | 12 | −70 | −125 | −138 | −67 | |
| Accounts payable | −38 | 21 | 1 | 33 | — | |
| Accrued compensation | −27 | 15 | 22 | — | — | |
| Income taxes payable, net | −94 | −15 | 44 | −7 | −44 | |
| Deferred revenue and customer advances | −23 | −53 | −600,000 | 53 | 39 | |
| Other changes in operating assets and liabilities, net | −30 | 24 | −28 | −18 | −19 | |
| Net cash provided by operating activities | 134 | 251 | 350 | 274 | 282 | |
| Purchases of property, plant and equipment | −91 | −115 | −107 | −129 | −92 | |
| Cash paid for minority investments | −7 | −48 | −25 | −60 | −500,000 | |
| Cash paid for business combinations, net of cash acquired | −74 | −1,600 | −227 | −182 | −65 | |
| Cash paid for in-process research and development and related assets | −29 | 0 | 0 | — | — | |
| Other investing activities, net | 5 | 6 | 32 | — | — | |
| Net cash used in investing activities | −197 | −1,757 | −326 | −252 | −192 | |
| Repayments of revolving lines of credit | −779 | −1,213 | 0 | 0 | 0 | |
| Proceeds from revolving lines of credit | 751 | 1,250 | 0 | 0 | 0 | |
| Repayment of long-term debt | −467 | −135 | −24 | −111 | −800,000 | |
| Proceeds from long-term debt | 4 | 974 | 2 | 300,000 | 493 | |
| Proceeds from issuance of Series A Mandatory Convertible Preferred Stock, net of issuance costs | 670 | 0 | 0 | — | — | |
| Proceeds from issuance of common stock, net | 8 | 409 | 10 | 3 | 7 | |
| Payment of dividends to Series A Mandatory Convertible Preferred Shareholders | −10 | 0 | 0 | — | — | |
| Payment of dividends to common shareholders | −23 | −30 | −29 | −30 | −24 | |
| Repurchase of common stock | −10 | 0 | −152 | −263 | −153 | |
| Other financing activities, net | −8 | −25 | 300,000 | — | — | |
| Net cash provided by (used in) financing activities | 135 | 1,230 | −193 | −415 | 319 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 44 | −29 | 12 | −31 | −23 | |
| Net change in cash, cash equivalents and restricted cash | 116 | −305 | −157 | −423 | 386 | |
| Cash paid for interest | 71 | 55 | 34 | 24 | 20 | |
| Cash paid for taxes | 223 | 154 | 97 | 147 | 146 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BRUKER CORP's CIK number?
BRUKER CORP's SEC CIK number is 0001109354 (1109354). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BRUKER CORP's SEC filings?
All of BRUKER CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did BRUKER CORP last report earnings?
BRUKER CORP (BRKR) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-207498). This is BRUKER CORP's most recent earnings filing of record — not a forecast of its next earnings date.
What is BRUKER CORP's most recent earnings 8-K?
BRUKER CORP's latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-207498. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View BRUKER CORP's latest earnings 8-K →
Look up any company's CIK number →